Literature DB >> 7045558

Resistance of the mouse to the antifertility effects of LHRH agonists.

F J Bex, A Corbin, E France.   

Abstract

In the mouse, the LH-releasing activity of the LHRH agonist, D-Trp6-N alpha-MeLeu7-DesGly10-Pro9-NHEt-LHRH (Wy-40,972), was established by its ability both to induce ovulation when administered at 1600 hours on the the second day of diestrus and to elevate serum LH in adult males. While Wy-40,972 was only slightly less active in terms of these and points than it was in the rat, the predictive and possibly causal association between LH-releasing and antifertility activity established for this LHRH analog in the rat could not be clearly identified in the mouse. A total daily dose of 1000 microgram Wy-40,972/mouse was required to completely inhibit pregnancy during days 1-7 of pregnancy and produced only partial inhibition during days 7-12. This dose represents, on a body weigh basis, 8250 times the 100 percent effective pregnancy-terminating dose for the rat during equivalent intervals. The resistance of the mouse to the antifertility activity of Wy-40,972 was found not to be restricted to this particular LHRH analog or to the reproductive state. Administration of another potent LHRH analog, D-Ala6-DesGly10-Pro9-NHEt-LHRH (Wy-18,481), to adult male mice at a dose of 100 microgram/mouse/day for up to 14 days had no inhibitory effect on the weights of the testes or sex accesory organs. This dose of Wy-18,481 is 7500 times that necessary for significant reduction of these reproductive organ weights in rats within 7 days of treatment. Investigation as to the nature of the mouse's apparently divergent response to the LHRH agonists may further elucidate the antifertility mechanism of such compounds in susceptible species.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7045558     DOI: 10.1016/0024-3205(82)90688-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Investigation of the influence of a cyclic luliberin analog on ovulation.

Authors:  V V Korkhov; V P Makusheva; G E Lupanova; S V Burov; S V Nikolaev
Journal:  Neurosci Behav Physiol       Date:  1986 Nov-Dec

Review 2.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

3.  Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630).

Authors:  G J van Steenbrugge; J C Romijn; F H de Jong; F H Schröder
Journal:  Urol Res       Date:  1984

4.  Detection of androgen receptors in human esophageal cancer.

Authors:  Y Yamashita; T Hirai; H Mukaida; K Kawano; T Toge; M Niimoto; T Hattori
Journal:  Jpn J Surg       Date:  1989-03

5.  Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.

Authors:  R W Lewis; K J Dowling; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

8.  From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.

Authors:  A Corbin
Journal:  Yale J Biol Med       Date:  1982 Jan-Feb
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.